The joint stock company Grindeks (Unified Reg. No. 40003034935, Legal address: 53 Krustpils St., Riga, LV – 1057, Latvia) announces that the shareholder “ABLV Private Equity Fund 2010”, KS (Unified Reg. No. 40103307758, Legal address: 23 Elizabetes St., Riga, LV – 1010, Latvia), which represents voting capital of joint stock company Grindeks in the total amount of 22.66%, has submitted following draft resolutions of items included in the agenda of joint stock company Grindeks Extraordinary General Meeting of shareholders to be held on 11 November 2014 at 11 a.m. at premises of joint stock company Grindeks, 53 Krustpils street, Riga, Latvia: 

A. To take the following decision on the first item “Distribution of the profit for the year 2013”:

1) To pay in dividends to shareholders from the net profit for the year 2013 EUR 0.52 per one share and to leave undistributed rest of the profit and to use it for the development of joint stock company Grindeks to increase the competitiveness of joint stock company Grindeks. The total amount to be paid in dividends is EUR 4 984 200.

2) To propose 25 November 2014 as the dividend record date and 30 November 2014 as the dividend payment date.

B. To take the following decision on the second item ”Election of the Supervisory Council” (in accordance with the procedure established in the Commercial Law regarding reelection of Supervisory Council):

1) To recall Supervisory Council  members Janis Naglis, Kirovs Lipmans, Anna Lipmane un Arkadiy Vertkin from the office of the members of joint stock company Grindeks Supervisory Council.

2) To elect for the office of the member of joint stock company Grindeks Supervisory Council  for the term three years, starting on 11 November 2014:

  1. 1. Janis Naglis;
  2. 2. Kirovs Lipmans;
  3. 3. Anna Lipmane;
  4. 4. Arkadiy Vertkin;
  5. 5. Agris Grinbergs.

The shareholder “ABLV Private Equity Fund 2010”, KS has nominated Agris Grīnbergs (CV enclosed) as a candidate of the member of joint stock company Grindeks Supervisory Council.

Draft Resolutions prepared by the Management Board of joint stock company Grindeks in accordance with the Article 273 part 5 of Commercial law will be published no later than fourteen days prior to the Extraordinary General Meeting to be held on 11 November 2014.

Agris Grīnbergs CV (66 KB)

About Grindeks

Grindeks is the leading pharmaceutical company in the Baltic States. Main fields of action are research, development, manufacturing and sales of original products, generics and active pharmaceutical ingredients. Grindeks Group consists of 4 subsidiary companies in Latvia, Estonia and Russia; representative offices are opened in 13 countries.

Grindeks specializes in the heart and cardiovascular, CNS and anti-cancer medication therapeutic groups. The portfolio of Grindeks products consists of successful combination of branded products and generic medications – including brand products Mildronate® and Ftorafur®, as well as more than 100 effective and safe medications. Currently Grindeks manufactures 25 active pharmaceutical ingredients.

Products of the company are exported to 59 countries and its export comprises more than 95% of the total turnover. The main markets are: Russia and other CIS countries, the Baltic States, Germany, the Netherlands, Japan and the U.S.

To increase production capacity and develop infrastructure, since 2002 the company has accomplished many significant investment projects, investing 70.7 million euros over the years.

JSC Grindeks shares are listed on the Official List of “Nasdaq OMX Riga”. Major shareholders of JSC Grindeks are Kirovs Lipmans – 33.29%, “AB.LV Private Equity fund 2010” – 22.66%, Anna Lipmane – 16.69%, “Swedbank” AS Clients Account (nominee account) – 10.47%.

More information about the company – www.grindeks.lv/en/

Additional information:

Laila Klavina
Head of the Communications Department JSC Grindeks
Phones: (+371) 67083370, (+371) 29256012
Fax: (+371) 67083505
E-mail: laila.klavina@grindeks.lv